Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael Max; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kähler, Katharina C.; French, Lars E.; Heinzerling, Lucie

doi:10.1016/j.dib.2022.108676

Data in Brief

2022

DOI: 10.1016/j.dib.2022.108676

|View full text |Cite

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Thomas U. Schulz

Sarah Zierold

Michael Max Sachse

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Profili,

Castelli,

Gidaro

et al. 2023

JCM

View full text Add to dashboard Cite

Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by stimulating immune system. Their use has improved the treatment of different types of cancer such as melanoma, breast carcinoma, lung, stomach, colon, liver, renal cell carcinoma, and Hodgkin’s lymphoma, but several adverse events have been reported. Although the etiology of these effects is not completely understood, an uncontrolled activation of the immune system has been postulated. Indeed, some studies showed a cross reactivity of T cells, which acted against tumor antigens as well as antigens in the tissues of patients who developed immune-related adverse events. Despite the known possibility of developing immune-related adverse events, early diagnosis, monitoring during therapy, and treatment are fundamental for the best supportive care and administration of immune checkpoint inhibitors. The aim of this review is to guide the clinician in early diagnosis, management, and treatment of the endocrinological adverse effects in the major endocrine glands (thyroid, pituitary, adrenal, endocrine pancreas, and parathyroid).

show abstract

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Profili,

Castelli,

Gidaro

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Cited by 1 publication

References 9 publications

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Contact Info

Product

Resources

About